期刊文献+

2001—2013年邯郸市他汀类药物不良反应分析 被引量:17

Analysis on adverse drug reaction induced by statins in Handan City from 2001 to 2013
原文传递
导出
摘要 目的了解邯郸市各医院使用的他汀类药物不良反应(ADR)发生情况,为临床合理用药提供依据。方法对邯郸市药品不良反应监测机构上报的2001—2013年他汀类药物不良反应登记资料进行回顾性统计分析。结果 ADR累及多个系统–器官,主要包括肝胆、胃肠、肌肉骨骼及神经系统,其他系统相对少见。严重不良反应以肝损害最常见;不同他汀类ADR有所差异,辛伐他汀主要累及肌肉骨骼、胃肠系统和肝胆系统,阿托伐他汀主要累及肝胆和神经系统,氟伐他汀主要累及胃肠系统。结论目前在临床上应用的他汀类药物在常规剂量范围内均有ADR发生,应规范降脂用药剂量和时限,减少不良反应发生。 Objective To analyze the adverse drug reaction (ADR) induced by statins in Handan City, and to provide the reference for clinical rational drug usage. Methods ADRs of statins reported by Handan ADR monitoring agencies from 2001 to 2013 were retrospectively analyzed. Results ADRs involved multiple system organs including hepatobiliary system, gastrointestinal system, muscles, bones, and nervous system, while the other systems were relatively uncommon. The serious ADRs frequently involved liver dysfunction. Different kinds of statins could induce different ADR. Simvastatin mainly involved musculoskeletal, gastrointestinal, and hepatobiliary systems, and at the same time, atorvastatin mainly involved the hepatobiliary and nervous systems. Fluorine mainly affected the gastrointestinal system. Conclusion At present, ADR can occur in all statins at regular dosage range in the clinical application, and lipid-lowering drugs should be strictly regulated by dosage and time-limit, so as to reduce the incidence of ADR.
出处 《现代药物与临床》 CAS 2014年第5期536-540,共5页 Drugs & Clinic
关键词 他汀类药物 降脂药物 药品不良反应 统计分析 statins lipid-lowering drug adverse drug reaction statistical analysis
  • 相关文献

参考文献9

二级参考文献64

  • 1蒋彦章.WHO全球药物不良反应信息(16)[J].药物流行病学杂志,2005,14(3):189-190. 被引量:2
  • 2THOMPSON PD,CLARKSON P,KARAS RH.Statin-associated myopathy[J].JAMA,2003,289 (13):1681-1690.
  • 3DAVIDSON MH.Controversy surrounding the safety of cerivastatin[J].Expert Opin Drug Saf,2002,1 (3):207-212.
  • 4STAFFA JA,CHANG J,GREEN L.Cerivastatin and reports of fatal rhabdomyolysis[J].N Engl J Med,2002,346(7):539-540.
  • 5RATZBRAVO AE,TCHAMBAZ L,KRAHENBUHL-MELCHER A,et al.Prevalence of potentially severe drug-drug interaction in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy[J].Drug Saf,2005,28 (3):203-275.
  • 6BELLOSTA S,PAOLETTI R,CORSINI A,et al.Safety of statins:focus on clinical pharmacokinetics and drug interactions[J].Circulation,2004,109(23 Suppl 1):Ⅲ 50-Ⅲ 57.
  • 7KAJINAMI K,TAKEKOSHI N,SAITO YL.Pitavastatin:efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor[J].Cardiovasc Drug Rev,2003,21 (3):199-215.
  • 8McKENNEY JM.Efficacy and safety of rosuvastatin in treatment of dyslipidemia[J].Am J Health Syst Pharm,2005,62(10):1033-1047.
  • 9THOMPSON PD,LARKSON P,KARAS RH.Statin-associated myopathy[J].JAMA,2003,289 (13):1681-1690.
  • 10DAVIDSON MH,TOTH PP.Comparative effects of lipid-lowering therapies[J].Prog Cardiovasc Dis,2004,47(2):73-104.

共引文献83

同被引文献197

引证文献17

二级引证文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部